Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial

被引:0
|
作者
Erik, Lars [1 ]
Keiserman, Mauro [2 ]
Papp, Kim A. [3 ,4 ]
McCasland, Leslie [5 ]
White, Douglas [6 ]
Stakias, Vassilis [7 ]
Iyile, Thomas [7 ]
Carter, Kyle [7 ]
Soliman, Ahmed [7 ]
Drogaris, Leonidas [7 ]
Chen, Michael [7 ]
Padilla, Byron [7 ]
Behrens, Frank [8 ,9 ]
机构
[1] Bispebjerg Frederiksberg Hosp, Vedbaek, Denmark
[2] Pontifical Catholic Univ, Sch Med, Porto Alegre, RS, Brazil
[3] Alliance Clin Res & Prob Med Res, Waterloo, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
[5] Arthrit & Rheumatism Associates, Jonesboro, AR USA
[6] Univ Auckland, Waikato Clin Sch, Hamilton, New Zealand
[7] AbbVie Inc, N Chicago, IL USA
[8] Goethe Univ, Frankfurt, Germany
[9] Fraunhofer ITMP, Frankfurt, Germany
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1435
引用
收藏
页码:2826 / 2829
页数:4
相关论文
共 50 条
  • [1] Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
    Ostor, Andrew
    Van den Bosch, Filip
    Papp, Kim A.
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Stakias, Vassilis
    Iyile, Thomas
    Carter, Kyle
    Soliman, Ahmed
    Drogaris, Leonidas
    Chen, Michael
    Padilla, Byron
    Kivitz, Alan
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2823 - 2826
  • [2] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients
    Lidar, Merav
    Aelion, Jacob
    Tarr, Gareth Scott
    Papp, Kim
    Barcomb, Lisa
    Soliman, Ahmed M.
    Lu, Wenjing
    Eldred, Ann
    Ostor, Andrew
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 368 - 369
  • [3] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
    Erik, Lars
    Papp, Kim
    White, Douglas
    Asnal, Cecilia
    Lu, Wenjing
    Soliman, Ahmed
    Padilla, Byron
    Chen, Michael
    Ostor, Andrew
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4255 - 4258
  • [4] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    McCasland, Leslie
    White, Douglas
    Lu, Wenjing
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Behrens, Frank
    [J]. RHEUMATOLOGY, 2023, 62 (06) : 2113 - 2121
  • [5] EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PSA): 52-WEEK RESULTS FROM KEEPSAKE 1
    Kristensen, L. E.
    Keiserman, M.
    Papp, K.
    Mccasland, L.
    White, D.
    Lu, W.
    Soliman, A. M.
    Eldred, A.
    Barcomb, L.
    Behrens, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 823 - 824
  • [6] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Carter, Kyle
    Stakias, Vassilis
    Lippe, Ralph
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael M.
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 633 - 648
  • [7] Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Carter, Kyle
    Stakias, Vassilis
    Lippe, Ralph
    Drogaris, Leonidas
    Soliman, Ahmed M.
    Chen, Michael M.
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 633 - 648
  • [8] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study
    Ostor, Andrew
    van den Bosch, Filip
    Papp, Kim
    Asnal, Cecilia
    Blanco, Ricardo
    Aelion, Jacob
    Lu, Wenjing
    Wang, Zailong
    Soliman, Ahmed M.
    Eldred, Ann
    Padilla, Byron
    Kivitz, Alan
    [J]. RHEUMATOLOGY, 2023, 62 (06) : 2122 - 2129
  • [9] Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
    Philip J. Mease
    Herbert Kellner
    Akimichi Morita
    Alan J. Kivitz
    Stella Aslanyan
    Steven J. Padula
    Andrew S. Topp
    Ann Eldred
    Frank Behrens
    Kim A. Papp
    [J]. Rheumatology and Therapy, 2022, 9 : 1361 - 1375
  • [10] Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
    Mease, Philip J.
    Kellner, Herbert
    Morita, Akimichi
    Kivitz, Alan J.
    Aslanyan, Stella
    Padula, Steven J.
    Topp, Andrew S.
    Eldred, Ann
    Behrens, Frank
    Papp, Kim A.
    [J]. RHEUMATOLOGY AND THERAPY, 2022, 9 (05) : 1361 - 1375